Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. on August 6, 2019. The filing announces the Company's financial results for the quarter ended June 30, 2019, and provides operational updates. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing serves as a notification that these results were announced and directs readers to the press release furnished as Exhibit 99.1 for the full details.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
The Company provided operational updates alongside the financial results, though specific guidance or outlook figures are not detailed in the 8-K text itself. The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, limiting its incorporation by reference in other filings.
Key Facts for Investor Verification
- Verify the specific financial figures for the quarter ended June 30, 2019, by reviewing Exhibit 99.1 (Press Release) as they are not listed in the 8-K body.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Review the operational updates mentioned in the press release to understand the context of the financial results.
- Note that the financial information in this filing is not deemed "filed" under Section 18 of the Exchange Act.